Literature DB >> 15337665

Folate, homocysteine, and negative symptoms in schizophrenia.

Donald C Goff1, Teodoro Bottiglieri, Erland Arning, Vivian Shih, Oliver Freudenreich, A Eden Evins, David C Henderson, Lee Baer, Joseph Coyle.   

Abstract

OBJECTIVE: Because glutamate carboxypeptidase II (GCPII) regulates both folate absorption and activation of N-methyl-d-aspartic acid receptors, the authors examined relationships between serum folate concentrations and clinical symptoms in schizophrenia patients.
METHOD: For 91 outpatients with schizophrenia, clinical assessments were performed and serum folate, homocysteine, B(12), glycine, and serine concentrations were measured.
RESULTS: Serum folate concentrations were significantly lower than in a representative sample from the Framingham Offspring Study. Folate concentration correlated inversely with the Scale for Assessment of Negative Symptoms total score and was lower in patients with the deficit syndrome than in nondeficit patients. Homocysteine concentration correlated with the severity of extrapyramidal symptoms.
CONCLUSIONS: These findings could reflect several possible mechanisms, including low dietary intake of folate, low GCPII activity, cigarette smoking, and the involvement of folate in the synthesis of neurotransmitters. Additional studies are needed to clarify these findings.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15337665     DOI: 10.1176/appi.ajp.161.9.1705

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  32 in total

1.  Ketamine-induced behavioural and brain oxidative changes in mice: an assessment of possible beneficial effects of zinc as mono- or adjunct therapy.

Authors:  Olakunle James Onaolapo; Olayemi Quyyom Ademakinwa; Temitayo Opeyemi Olalekan; Adejoke Yetunde Onaolapo
Journal:  Psychopharmacology (Berl)       Date:  2017-06-14       Impact factor: 4.530

2.  Taking Personalized Medicine Seriously: Biomarker Approaches in Phase IIb/III Studies in Major Depression and Schizophrenia.

Authors:  Harald Murck; Thomas Laughren; Femke Lamers; Rosalind Picard; Sebastian Walther; Donald Goff; Stephen Sainati
Journal:  Innov Clin Neurosci       Date:  2015 Mar-Apr

3.  Homocysteine and cognition in first-episode psychosis patients.

Authors:  Rosa Ayesa-Arriola; Rocío Pérez-Iglesias; José Manuel Rodríguez-Sánchez; Ignacio Mata; Elsa Gómez-Ruiz; Maite García-Unzueta; Obdulia Martínez-García; Rafael Tabares-Seisdedos; Jose L Vázquez-Barquero; Benedicto Crespo-Facorro
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2012-03-02       Impact factor: 5.270

Review 4.  Vitamin supplementation in the treatment of schizophrenia.

Authors:  Hannah E Brown; Joshua L Roffman
Journal:  CNS Drugs       Date:  2014-07       Impact factor: 5.749

5.  Folic acid/methylfolate for the treatment of psychopathology in schizophrenia: a systematic review and meta-analysis.

Authors:  Kenji Sakuma; Shinji Matsunaga; Ikuo Nomura; Makoto Okuya; Taro Kishi; Nakao Iwata
Journal:  Psychopharmacology (Berl)       Date:  2018-05-22       Impact factor: 4.530

6.  Anticonvulsive effect of folic acid in homocysteine thiolactone-induced seizures.

Authors:  Aleksandra Rašić Marković; Dragan Hrnčić; Djuro Macut; Olivera Stanojlović; Dragan Djuric
Journal:  Cell Mol Neurobiol       Date:  2011-06-22       Impact factor: 5.046

Review 7.  [The influence of diet on mental health].

Authors:  C Hausteiner; S Bornschein; T Zilker; H Förstl; J Grassmann
Journal:  Nervenarzt       Date:  2007-06       Impact factor: 1.214

8.  Deficit schizophrenia: an update.

Authors:  Brian Kirkpatrick; Silvana Galderisi
Journal:  World Psychiatry       Date:  2008-10       Impact factor: 49.548

9.  Future perspectives on the treatment of cognitive deficits and negative symptoms in schizophrenia.

Authors:  Donald C Goff
Journal:  World Psychiatry       Date:  2013-06       Impact factor: 49.548

10.  Promoter analysis of human glutamate carboxypeptidase II.

Authors:  Liqun Han; Dona Lee Wong; Guochuan Tsai; Zhichun Jiang; Joseph T Coyle
Journal:  Brain Res       Date:  2007-07-17       Impact factor: 3.252

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.